Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro
새로운 SARS-CoV-2 시험관 내 바이러스 프로테아제 억제제의 비교 항바이러스 효능
Article
[키워드] (Lopinavir/ritonavir
Analysis
Antiviral
antiviral efficacy
best
carried
caused
Clinical use
Comparative
compounds
Concentration
coronavirus
Coronavirus infection
Coronavirus pneumonia
COVID-19
dosage
effective
evaluated
experimental evidence
Health Organization
Human immunodeficiency virus
identifying
in silico
in vitro
in vivo
information
inhibitor
inhibitory
inhibitory effect
Kaletra
Lopinavir
Lopinavir/ritonavir
mechanism
New coronavirus
novel
Novel coronavirus
Novel coronavirus infection
novel coronavirus pneumonia
outbreak
patients
pharmacokinetics
plasma concentration
Pneumonia
protease
Protease inhibitor
provided
public health
regimen
Research
respiratory
Respiratory pharmacology
Ritonavir
Safe
SARS-CoV-2
Solidarity trial
suggested
Support
tablets
targets
tested
Viral
World Health Organization
[DOI] 10.1007/s12250-020-00288-1 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s12250-020-00288-1 PMC 바로가기 [Article Type] Article